Top Markets
#1 Nesa Nesa +816.36%
#2 Cortex Cortex +69.03%
#3 Kinesis Silver Kinesis Silver +57.40%
#4 Merlin's Seal BTC Merlin's Seal BTC +45.76%
#5 QuantixAI QuantixAI +24.05%
#6 EXOD EXOD +22.78%
#7 OpenEden OpenEden +19.32%
#8 Palladium Network Palladium Network +18.94%
#9 Cash Cat Cash Cat +18.07%
#10 Instadapp Instadapp +16.15%
Coin of the day
Nesa Nesa
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Shanghai Junshi Biosciences Co., Ltd. Shanghai Junshi Biosciences Co., Ltd.

Shanghai Junshi Biosciences Co., Ltd.

688180
Kedudukan dalam Saham #3521
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise... Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative therapeutic agents. Operating within the People's Republic of China, their focus spans critical medical areas such as oncology, metabolic diseases, autoimmune disorders, neurological conditions, and infectious diseases. Among its principal offerings is JS001, commercialized as TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for a broad spectrum of cancer indications, including various forms of melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond TUOYI, Junshi Biosciences boasts a robust pipeline of investigational drugs. These include UBP1211, a biosimilar of Humira, targeting conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody aimed at hyperlipidemia; and UBP1213, a recombinant humanized anti-BLyS monoclonal antibody in injectable form. Further developments encompass JS501, a biosimilar to Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, identified as a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. The company has also established strategic collaborations. Notably, it partners with Eli Lilly and Company on the co-development of therapeutic antibodies intended for the prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Additionally, an alliance with Coherus Biosciences, Inc. facilitates the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its corporate headquarters in Shanghai, People's Republic of China.
Harga Saham
$5.14
Modal Pasaran
$5.24B
Perubahan (1 hari)
0.65%
Perubahan (1 tahun)
-18.58%
Negara
CN
Perdagangan Shanghai Junshi Biosciences Co., Ltd. (688180)

Kategori

Healthcare
Pendapatan untuk Shanghai Junshi Biosciences Co., Ltd. (688180)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Shanghai Junshi Biosciences Co., Ltd., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Shanghai Junshi Biosciences Co., Ltd. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH